华东医药在互动平台表示，公司用于治疗铂耐药卵巢癌的全球首创ADC药物 HDM2002（IMGN853）、用于治疗成年中重度斑块状银屑病的原研药乌司奴单抗（Stelara，喜达诺）的生物类似药HDM3001（QX001S）有望于今年在国内递交BLA；与 MediBeacon肾小球滤过率动态监测系统配合使用的荧光示踪剂MB-102注射液有望于今年递交上市申请；公司迈华替尼片目前正在进行III期临床试验，预计有望于今年递交上市申请；利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症均有望在今年获批上市。
Huadong Pharmaceutical said on the interactive platform that the company's pioneering ADC drug HDM2002 (IMGN853) for the treatment of platinum-resistant ovarian cancer and HDM3001 (QX001S), a biosimilar drug of ussenumab (Stelara, Sidano) for treating moderate to severe plaque psoriasis in adults, are expected to submit BLA in China this year; the fluorescence tracer MB-102 injection used in conjunction with the MediBeacon glomerular filtration rate dynamic monitoring system is expected to submit an application for marketing this year; the company's mevatinib tablets are currently being marketed Phase III clinical trials have been conducted, and it is expected that marketing applications will be submitted this year; liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year.
